HUP0400030A2 - Antibodies specific for cd44v6 - Google Patents

Antibodies specific for cd44v6

Info

Publication number
HUP0400030A2
HUP0400030A2 HU0400030A HUP0400030A HUP0400030A2 HU P0400030 A2 HUP0400030 A2 HU P0400030A2 HU 0400030 A HU0400030 A HU 0400030A HU P0400030 A HUP0400030 A HU P0400030A HU P0400030 A2 HUP0400030 A2 HU P0400030A2
Authority
HU
Hungary
Prior art keywords
cd44v6
antibodies specific
antibodies
specific
Prior art date
Application number
HU0400030A
Other languages
Hungarian (hu)
Inventor
Günther Adolf
Augustinus Antonius Maria Silvester Dongen
Karl-Heinz Heider
John J. Miglietta
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Original Assignee
Boehringer Ingelheim International Gmbh.
Boehringer Ingelheim Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh., Boehringer Ingelheim Pharmaceuticals Inc. filed Critical Boehringer Ingelheim International Gmbh.
Publication of HUP0400030A2 publication Critical patent/HUP0400030A2/en
Publication of HUP0400030A3 publication Critical patent/HUP0400030A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
HU0400030A 2001-05-18 2002-05-17 Antibodies specific for cd44v6 HUP0400030A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US32514701P 2001-09-26 2001-09-26
PCT/EP2002/005467 WO2002094879A1 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Publications (2)

Publication Number Publication Date
HUP0400030A2 true HUP0400030A2 (en) 2004-04-28
HUP0400030A3 HUP0400030A3 (en) 2006-02-28

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400030A HUP0400030A3 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Country Status (18)

Country Link
EP (1) EP1397387A1 (en)
JP (1) JP2005504517A (en)
CN (1) CN1541226A (en)
AR (1) AR036154A1 (en)
BR (1) BR0210905A (en)
CA (1) CA2443437A1 (en)
CZ (1) CZ20033476A3 (en)
EA (1) EA200301169A1 (en)
EC (1) ECSP034838A (en)
EE (1) EE200300569A (en)
HU (1) HUP0400030A3 (en)
MX (1) MXPA03010523A (en)
PE (1) PE20021098A1 (en)
PL (1) PL365735A1 (en)
SK (1) SK15592003A3 (en)
WO (1) WO2002094879A1 (en)
YU (1) YU91403A (en)
ZA (1) ZA200307365B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
SG182191A1 (en) * 2007-06-13 2012-07-30 Zymogenetics Inc Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
SI2531527T1 (en) 2010-02-04 2014-07-31 F. Hoffmann-La Roche Ag A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma
CN102337298B (en) * 2011-08-19 2013-11-06 黄开红 Immune nano-carrier for conveying siRNA (small interfering Ribonucleic Acid) and preparation method and application thereof
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
WO2017215637A1 (en) * 2016-06-15 2017-12-21 李翀 Human endometrial cancer marker, antibody, and application of antibody
CN107556388A (en) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 The double targeting antibodies of anti-CD44v6 and CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application
EP4114860A1 (en) * 2020-03-06 2023-01-11 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
EP4301782A1 (en) * 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
JPH08506801A (en) * 1992-11-20 1996-07-23 アイシス・イノベーション・リミテッド Peptides corresponding to CD44 exon 6, antibodies specific to the peptides, and methods of using these antibodies for tumor diagnosis
UA58482C2 (en) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх MONOCLONAL ANTIBODY VFF-18 AGAINST CD44V6 AND ITS FRAGMENTS
UY24389A1 (en) * 1995-12-06 2001-10-25 Karlsruhe Forschzent PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FLAT EPITHELIUM CARCINOMA

Also Published As

Publication number Publication date
CN1541226A (en) 2004-10-27
WO2002094879A1 (en) 2002-11-28
CZ20033476A3 (en) 2004-05-12
PL365735A1 (en) 2005-01-10
PE20021098A1 (en) 2003-02-11
EA200301169A1 (en) 2004-06-24
HUP0400030A3 (en) 2006-02-28
ECSP034838A (en) 2003-12-24
YU91403A (en) 2006-05-25
EE200300569A (en) 2004-04-15
CA2443437A1 (en) 2002-11-28
BR0210905A (en) 2004-06-08
JP2005504517A (en) 2005-02-17
MXPA03010523A (en) 2004-07-01
ZA200307365B (en) 2004-05-10
AR036154A1 (en) 2004-08-18
EP1397387A1 (en) 2004-03-17
SK15592003A3 (en) 2004-06-08

Similar Documents

Publication Publication Date Title
EP1432444A4 (en) Anti-a-beta antibodies
EP1467756A4 (en) Methods for using anti-muc18 antibodies
EP1494693A4 (en) Cripto-specific antibodies
PL375405A1 (en) Antibodies
AU2002256895A1 (en) Anti-TRAIL-R antibodies
PT1599504E (en) Modified antibody
GB0426043D0 (en) Antibodies
AU2002365649A8 (en) Anti-dota antibody
HUP0400030A3 (en) Antibodies specific for cd44v6
EP1437410A4 (en) Novel selenocystein-containing proteins
IL163580A0 (en) Assay for anti-ingap antibodies
GB0306618D0 (en) Antibody
GB0226878D0 (en) Antibodies
GB0105402D0 (en) Novel proteins
HRP20030931A2 (en) Antibodies specific for cd44v6
GB0031284D0 (en) High affinity antibodies
GB0118696D0 (en) Novel antibodies
GB0119553D0 (en) Antibodies
GB0217742D0 (en) Novel antibodies
GB0105401D0 (en) Novel proteins
GB0100750D0 (en) Novel proteins
GB0120494D0 (en) Novel antibody
GB0218235D0 (en) Antibodies
GB0210508D0 (en) Antibodies
GB0218232D0 (en) Antibodies

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees